Matuzumab
Matuzumab
Matuzumab (pronunciation: ma-too-zoo-mab) is a monoclonal antibody designed for the treatment of cancer. It was developed by Merck KGaA, a German multinational pharmaceutical, chemical and life sciences company.
Etymology
The name "Matuzumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" is used for all these types of antibodies, while the prefix "matu-" does not have a specific meaning and is used to create a unique name.
Mechanism of Action
Matuzumab works by targeting the epidermal growth factor receptor (EGFR), which is often overexpressed in certain types of cancer. By binding to the EGFR, matuzumab can inhibit the growth and proliferation of cancer cells.
Clinical Trials
Matuzumab has been tested in several clinical trials for various types of cancer, including colorectal cancer, non-small cell lung cancer, and gastric cancer. However, the results have been mixed, and as of now, matuzumab is not approved for use in any country.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Epidermal growth factor receptor (EGFR): A protein found on the surface of some cells to which epidermal growth factor binds, causing the cells to divide.
- Clinical trial: A research study that tests how well new medical approaches work in people.
External links
- Medical encyclopedia article on Matuzumab
- Wikipedia's article - Matuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski